ライフサイエンスコーパス: primary aldosteronism

1 rone:renin ratios (a screening parameter for primary aldosteronism).

2 e approach to the diagnosis and subtyping of primary aldosteronism.

3 the development of new treatment options for primary aldosteronism.

4 tive value for detecting biochemically overt primary aldosteronism.

5 th systems suggests low rates of testing for primary aldosteronism.

6 y 6 hours for 4 days) to diagnose or exclude primary aldosteronism.

7 nd follow-up of adrenalectomy for unilateral primary aldosteronism.

8 ists are the recommended medical therapy for primary aldosteronism.

9 ble way to correctly diagnose the subtype of primary aldosteronism.

10 ng from Cav1.3 hyperactivity, in particular, primary aldosteronism.

11 tension including obstructive sleep apnea or primary aldosteronism.

12 unction Ca(2+) channel mutations in APAs and primary aldosteronism.

13 o renin ratio is a useful screening tool for primary aldosteronism.

14 nsion often persists after adrenalectomy for primary aldosteronism.

15 xpanded extracellular fluid volume, e.g., in primary aldosteronism.

16 t 4 was considered indicative of lateralized primary aldosteronism.

17 isk is observed even in subclinical forms of primary aldosteronism according to studies conducted pri

18 escape phenomenon is clinically relevant as primary aldosteronism affects nearly one in ten hyperten

19 Patients with primary aldosteronism also had higher adjusted risks for

20 nd follow-up of adrenalectomy for unilateral primary aldosteronism and apply these criteria to an int

21 PAs and has the potential to completely cure primary aldosteronism and hypertension when most of the

22 ies to tackle GIRK4-related diseases such as primary aldosteronism and late-onset obesity.

23 Classical primary aldosteronism and lesser degrees of aldosterone

24 Until the true prevalence of primary aldosteronism and monogenic forms of mineralocor

25 a previously undescribed syndrome featuring primary aldosteronism and neuromuscular abnormalities.

26 med our understanding of the pathogenesis of primary aldosteronism and of its clinical phenotypes.

27 nin levels, as a confirmatory diagnostic for primary aldosteronism and to quantify the magnitude of r

28 ociations between resistant hypertension and primary aldosteronism and with obstructive sleep apnea.

29 se, which spans subclinical stages to florid primary aldosteronism, and from single-focal or multifoc

30 a detailed insight in the genetic causes of primary aldosteronism, and mineralocorticoid receptor bl

31 uggests that milder and subclinical forms of primary aldosteronism are highly prevalent, yet their co

32 100 patients who underwent adrenalectomy for primary aldosteronism at one tertiary medical center and

33 No association was found between primary aldosteronism biomarkers and measures of arteria

34 udy aimed to assess whether early changes in primary aldosteronism biomarkers during young adulthood

35 t diet (relative autonomy, characteristic of primary aldosteronism), but plasma aldosterone was only

36 ssment of patients diagnosed with unilateral primary aldosteronism by adrenal venous sampling who had

37 unrelated subjects with hypertension due to primary aldosteronism by age 10.

38 ues for an orthogonal treatment approach for primary aldosteronism by specifically targeting the inte

39 Background Primary aldosteronism can arise from one or both adrenal

40 Primary aldosteronism, characterized by overt renin-inde

41 Primary aldosteronism, characterized by renin-independen

42 Primary aldosteronism comprises subtypes that need diffe

43 f mineralocorticoid hypertension is probably primary aldosteronism; controlled posture studies to mea

44 Adrenal tumors driving hormone excess, like primary aldosteronism, Cushing syndrome, and pheochromoc

45 The dichotomous paradigm of primary aldosteronism diagnosis and subtyping is being r

46 s occur in a handful of conditions including primary aldosteronism, distal renal tubular acidosis, Li

47 of radiofrequency (RF) ablation in treating primary aldosteronism due to aldosterone-producing adeno

48 We present an interesting case of primary aldosteronism in which planar scintigraphy and S

49 ongitudinal study using data from the Taiwan Primary Aldosteronism Investigation database.

50 Primary aldosteronism is a common cause of hypertension

51 Primary aldosteronism is a common cause of treatment-res

52 Primary aldosteronism is a nonsuppressible renin-indepen

53 Primary aldosteronism is a potentially curable cause of

54 current practice of MR antagonist therapy in primary aldosteronism is associated with significantly h

55 Primary aldosteronism is common among patients with resi

56 The prevalence of primary aldosteronism is high and largely unrecognized.

57 tion of hypertension after adrenalectomy for primary aldosteronism is independently associated with a

58 l BP, a biochemical phenotype of subclinical primary aldosteronism is negatively associated with card

59 Primary aldosteronism is recognized as a severe form of

60 Primary aldosteronism is the most common curable cause o

61 Primary aldosteronism is the most common single cause of

62 Although unilateral primary aldosteronism is the most common surgically corr

63 in members of four kindreds with early onset primary aldosteronism of unknown cause.

64 ovascular events was higher in patients with primary aldosteronism on MR antagonists than in patients

65 S1R genes are involved in the development of primary aldosteronism (PA) and hypercortisolism [Cushing

66 pertensive population the true prevalence of primary aldosteronism (PA) and its main subtypes, aldost

67 Primary aldosteronism (PA) causes excess left ventricula

68 Primary aldosteronism (PA) causes hypertension and is po

69 Primary aldosteronism (PA) due to a unilateral aldostero

70 xcess aldosterone secretion in patients with primary aldosteronism (PA) impairs their cardiovascular

71 Primary aldosteronism (PA) is a common and underdiagnose

72 Primary aldosteronism (PA) is a common cause of secondar

73 Primary aldosteronism (PA) is a common, but frequently o

74 Primary aldosteronism (PA) is a common, potentially reve

75 Primary aldosteronism (PA) is common and associates with

76 Primary aldosteronism (PA) is one of the most common cau

77 Primary aldosteronism (PA) is the most common cause of s

78 Primary aldosteronism (PA) is the most common form of en

79 Primary aldosteronism (PA) is the most frequent form of

80 Adrenocortical hormone excess, due to primary aldosteronism (PA) or hypercortisolemia, causes

81 pharmacological treatments on outcomes among primary aldosteronism (PA) patients.

82 Primary aldosteronism (PA) represents the most common ca

83 Primary aldosteronism (PA) results from renin-independen

84 nous sampling (AVS) is crucial for subtyping primary aldosteronism (PA) to explore the possibility of

85 Primary aldosteronism (PA), an overt form of renin-indep

86 means to localize aldosterone production in primary aldosteronism (PA).

87 l interest in aiding clinical diagnostics in primary aldosteronism (PA).

88 igh prevalence and associated complications, primary aldosteronism remains largely under-recognized,

89 clinically relevant spectrum of subclinical primary aldosteronism (renin-independent aldosteronism)

90 Screening for primary aldosteronism should nonetheless be done in ever

91 The Primary Aldosteronism Surgical Outcome (PASO) study was

92 These findings redefine the primary aldosteronism syndrome and implicate it in the p

93 This Review discusses how redefining the primary aldosteronism syndrome as a multidimensional spe

94 Rates of primary aldosteronism testing (plasma aldosterone-renin)

95 Beyond this categorical definition of primary aldosteronism, there is a prevalent continuum of

96 ous and compensatory diuresis that occurs in primary aldosteronism to correct and rebalance fluid hom

97 The importance of primary aldosteronism to public health derives from its

98 We identified 602 eligible patients with primary aldosteronism treated with MR antagonists and 41

99 ident cardiovascular events in patients with primary aldosteronism treated with MR antagonists compar

100 aged 18 years or older, with a diagnosis of primary aldosteronism under the Endocrine Society's crit

101 t diabetes (NOD) in patients with unilateral primary aldosteronism (uPA) remains underexplored.

102 We identified patients with primary aldosteronism using International Classification

103 Primary aldosteronism was confirmed by using the oral so

104 Biochemically overt primary aldosteronism was diagnosed when urinary aldoste

105 reatment-resistant hypertension, testing for primary aldosteronism was rare and was associated with h

106 At 3-month follow-up, primary aldosteronism was resolved in 33 (92%) patients,

107 n-independent aldosteronism (ie, subclinical primary aldosteronism), was associated with increased ar

108 prevalence estimates for biochemically overt primary aldosteronism were 11.3% (CI, 5.9% to 16.8%), 15

109 two patients whose hypertension and periodic primary aldosteronism were cured by adrenalectomy.

110 4277 (1.6%) patients who were tested for primary aldosteronism were identified.

111 unction mutation is sufficient to cause mild primary aldosteronism, whereas loss of Ca(V)3.2 channel

112 Overproduction of aldosterone leads to primary aldosteronism, which is the most common form of

113 cross-sectional study assessed patients with primary aldosteronism who underwent simultaneous AVS at

114 re for identifying patients with lateralized primary aldosteronism who would benefit from surgery.

115 y clinical study of 677 participants without primary aldosteronism, who were studied on both high and

116 s and mortality was limited to patients with primary aldosteronism whose renin activity remained supp

117 ations for the diagnosis and pathogenesis of primary aldosteronism with and without adrenal hyperplas

118 iscovery that Cav1.3 gain-of-function causes primary aldosteronism with seizures, neurologic abnormal